Equities

Beijing Wantai Biological Pharmacy Enterprise Co Ltd

603392:SHH

Beijing Wantai Biological Pharmacy Enterprise Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)73.17
  • Today's Change-0.76 / -1.03%
  • Shares traded4.81m
  • 1 Year change+51.18%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6,2397,1941,654
Total Receivables, Net3,0834,0052,300
Total Inventory905869593
Prepaid expenses4010498
Other current assets, total357.051.97
Total current assets10,30212,1804,647
Property, plant & equipment, net2,8832,4131,812
Goodwill, net------
Intangibles, net643332295
Long term investments1,43291161
Note receivable - long term50210.04
Other long term assets168174140
Total assets15,71516,2307,046
LIABILITIES
Accounts payable300317193
Accrued expenses269310208
Notes payable/short-term debt173175235
Current portion long-term debt/capital leases131414
Other current liabilities, total1,9152,6691,715
Total current liabilities2,6703,4852,366
Total long term debt12812137
Total debt314310287
Deferred income tax--17--
Minority interest18322496
Other liabilities, total344180
Total liabilities3,0143,8882,580
SHAREHOLDERS EQUITY
Common stock1,268906607
Additional paid-in capital3,3123,729446
Retained earnings (accumulated deficit)8,2507,9063,413
Treasury stock - common(129)(200)--
Unrealized gain (loss)------
Other equity, total------
Total equity12,70112,3414,466
Total liabilities & shareholders' equity15,71516,2307,046
Total common shares outstanding1,2661,2661,232
Treasury shares - common primary issue2.222.220
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.